# RQ Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rq-biotechnology

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.rqbiotechnology.com
- Total disclosed funding: $113M
- Latest round: Series A (Jun 24, 2026)
- Investors on record: 8

## About

RQ Biotechnology Ltd., based in the UK, specializes in developing long-acting monoclonal antibodies for seasonal influenza, providing innovative solutions to combat severe viral diseases among vulnerable populations.Founded in 2022 and headquartered in London, UK, RQ Biotechnology Ltd. focuses on advanced biopharmaceutical research. The company has successfully completed one deal, securing GBP 85.5 mn in Series A funding on June 24, 2026, led by Frazier Healthcare Partners with participation from several other investors, including LifeArc and the University of Oxford Staff Pension Scheme. The company is led by CEO Mike Westby. RQ Biotechnology Ltd. specializes in the research and development of long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza. These products are designed to offer immediate and prolonged protection against severe viral diseases, particularly for immunocompromised individuals such as newborns, the elderly, and patients with chronic health conditions.RQ Biotechnology Ltd. generates revenue through collaborations with healthcare providers and institutions seeking innovative solutions for influenza prevention. Their strategic partnerships involve pharmaceutical companies and public health entities, facilitating the distribution of long-acting monoclonal antibodies, with a pricing structure based on negotiations reflecting the value of their technology.Following the GBP 85.5 mn raised in Series A funding on June 24, 2026, RQ Biotechnology Ltd. plans to allocate funds towards the clinical development of its RQB01 influenza antibody programme. The company aims to expand its product pipeline to include treatments for various respiratory viral diseases and explore new markets, particularly in North America, Europe, and Asia, as they develop their offerings.

## Funding rounds

- Series A, Jun 24, 2026, $113M — EQT, Frazier Healthcare Partners, Wellington Management, Forbion, University of Oxford Staff Pension Scheme, Oxford Sciences Enterprises, Monograph Capital, LifeArc

## Investors

- EQT (https://capitalatlas.ai/funds/eqt) — Series A
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series A
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A
- University of Oxford Staff Pension Scheme — Series A
- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Series A
- Monograph Capital (https://capitalatlas.ai/funds/monograph-capital) — Series A
- LifeArc (https://capitalatlas.ai/funds/lifearc) — Series A